Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacoeconomic research partnerships should be attractive to industry, OTA's Wagner says.

Executive Summary

PHARMACOECONOMIC RESEARCH PARTNERSHIPS -- WITH NO VETO FOR MARKETERS -- are in "pharmaceutical companies' best interests," Office of Technology Assessment Senior Associate Judith Wagner maintained in a presentation to the Biotechnology Industry Organization annual meeting May 24 in San Francisco. Drug companies will increasingly find it to their advantage to "help fund independent buyer-led studies of cost-effectiveness analyses," in light of recent FDA suggestions that pharmacoeconomic claims by manufacturers will likely require two adequate well-controlled trials, Wagner suggested.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel